Clinical efficacy of atezolizumab


Clinical efficacy of atezolizumab in PD-L1 selected subgroups defined by SP142 and 22C3 IHC assays in 2L+ NSCLC: results from the randomized OAK trial [1296O]Shirish Gadgeel, et al

The objective of this analysis is to evaluate PD-L1 expression in patients using the two FDA-approved PD-L1 IHC diagnostic assays, SP142 and 22C3 and to evaluate atezolizumab efficacy in populations defined as PD-L1-negative by each assay.

In addition to SP142 assays, 400 patients samples (biomarker-evaluable population [BEP]) from OAK were available for retrospective analysis by the 22C3 assay.

The majority (77%) of SP142 PD-L1 negative patients were also negative by the 22C3 assays.

  • OS was improved with atezolizumab in the subgroup defined as PD-L1 low/negative, as measured by either assay:
    • OS in TPS<1% (22C3) subgroup: HR = 0.61 (0.45, 0.84)
    • OS in TC0 and IC0 (SP142) subgroup: HR = 0.55 (0.37, 0.80)

These results demonstrate that atezolizumab improves survival in patients with PD-L1 negative tumors irrespective of the assay utilized and also confirm the primary results from the OAK trial that atezolizumab provides survival benefit in all patients with NSCLC regardless of PD-L1 status.

https://cslide.ctimeetingtech.com/library/esmo/browse/search/2gbH#2Bb3f0D5

Oscar Ma
Associate Manager, Medical Affairs
Lung Franchise
e-mail: oscar.ma@roche.com